Neurology

Showing 15 posts of 109 posts found.

Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment

November 7, 2023
Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration

Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …

Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

October 31, 2023
Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023
Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023
Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023
Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

September 14, 2023
Sales and Marketing License Agreement, Neurology, Pharmazz, Sun Pharma, Tyvalzi, sovateltide

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz in …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

headache

AbbVie’s Aquipta receives MHRA marketing authorisation

September 5, 2023
Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …

robina-weermeijer-ihfopazzjhm-unsplash_5

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

August 25, 2023
Medical Communications FDA, MS, Neurology, Sandoz

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …

money_pills_2

Biogen to acquire Reata Pharmaceuticals

July 31, 2023
Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …

BioIVT acquires PrecisionMed for neurology and oncology research

July 21, 2023
Sales and Marketing Neurology, Oncology, neurology, oncology

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …

alzheimers_brain

Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023
Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

The Gateway to Local Adoption Series

Latest content